Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments
BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights…